New Drug for ED

10:44 am Health Care

A new PDE-5 inhibitor avanafil (Stendra) is now FDA approved.

  • After treatment for 12 weeks, men randomized to the PDE-5 inhibitor had significantly greater improvement in the three principal endpoints of erectile dysfunction, vaginal penetration, and successful intercourse.
  • Increased receptor selectivity and a shorter half-life are the key features distinguishing avanafil from other members of the PDE-5 inhibitor class: sildenafil, tadalafil and vardenafil.
  • Men take avanafil on an as-needed basis 30 minutes before sexual activity.
  • In one study, men achieved erections as soon as 15 minutes after taking the drug. The rate of erections sufficient for intercourse increased from less than 15% to as much as 57% with avanafil versus 27% with placebo.
  • Most commonly reported side effects in clinical trials of avanafil were headache, flushing, nasal congestion, nasopharyngitis, and back pain.
  • A 40-week extension study involving patients from two of the randomized trials showed no increase in the frequency or severity of adverse effects associated with avanafil.

Comments are closed.